Debates in CLL: The Case for BTKi Monotherapy in 1L

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

Debates in CLL: The Case for BTKi Monotherapy in 1L

By XIV Eurasian Hematology-Oncology Congress - EHOC 2023 FEATURING Gerardo Musuraca

55 views

February 16, 2024

Comparing Monotherapy & Combinations in CLL

00:00

Progression-Free Survival in CLL Treatment Trials

05:27

Monotherapy Outcomes in CLL with TP53 Mutations

08:58

Considering BTK Inhibitor Toxicities in Treatment Choice

10:23

Comments 0

Leukemia

Clinical Case of BPDCN

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

H. Hamed

25 views

A 50-Year Personal Perspective on the Treatment of AML

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

C. Schiffer

160 views

Induction Therapy Choices and Responses of ALL in a Third World Coun…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Zafar

16 views

Is HSCT Necessary to Consolidate Hematological Remission After CAR-T…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

F. Saglio

43 views

BK Virus Infections in Pediatric Leukemia During Treatment

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

D. KaçAr

15 views

Molecular Characteristics and Treatment Response to COG-ALL Protocol…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

B. GüNer Yılmaz

8 views

Inaticabtagene Autoleucel Treatment in Adult R/R B-Cell ALL in China

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

L. Lulu

7 views

CLL: Future Perspectives and Unanswered Questions

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Ferrajoli

215 views

Debates in CLL: The Case for Combination Therapy in 1L

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Ibrahim

23 views